Review examines evidence that antidiabetic drugs including GLP-1 agonists may prevent and intercept cancer development, linking metabolic drug therapy to oncology.
Key findingReview examines evidence that antidiabetic drugs including GLP-1 agonists may prevent and intercept
What the researchers found
Review examines evidence that antidiabetic drugs including GLP-1 agonists may prevent and intercept cancer development, linking metabolic drug therapy to oncology.
Why it matters
These findings have significant implications for peptide-based therapeutic development and clinical practice.
The numbers in context
Review highlights increasing burden of obesity-related cancers, particularly liver, pancreatic, endometrial, and breast cancers.
How the study worked
Study design and methodology detailed in the full publication.
Who was studied
Review covering populations with obesity, type 2 diabetes, and obesity-related cancers
What this study cannot tell us
Study-specific limitations discussed in the full publication. Results should be interpreted within the context of study design.
How to read the evidence
Evidence assessment based on study design detailed in publication.
When this study was published
Published in 2025. Current peptide therapeutic research.
The bigger picture
This study contributes to the expanding understanding of how peptide-based therapeutics can be applied across medical specialties.
Questions still open
- What are the long-term implications?
- How do these results compare to existing evidence?
- What further research is needed?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives.
Seminars in cancer biology, 115, 40-52
Citation
Albini, Adriana; Cantelmo, Anna Rita; Mortara, Lorenzo; Noonan, Douglas M; Corso, Giovanni. (2025). Cancer prevention and interception with antidiabetic and anti-obesity drugs: Current and future perspectives.. Seminars in cancer biology, 115, 40-52. https://doi.org/10.1016/j.semcancer.2025.07.008